References analysis of the Wikipedia article "CTLA4" in the Galician version

doi.org

dx.doi.org

Syn, Nicholas L; Teng, Michele W L; Mok, Tony S K; Soo, Ross A. "De-novo and acquired resistance to immune checkpoint targeting". The Lancet Oncology (en inglés) 18 (12): e731–e741. doi:10.1016/s1470-2045(17)30607-1.

Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, Golstein P (1987). "A new member of the immunoglobulin superfamily--CTLA-4". Nature 328 (6127): 267–70. PMID 3496540. doi:10.1038/328267a0.

Dariavach P, Mattéi MG, Golstein P, Lefranc MP (decembro de 1988). "Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains". Eur. J. Immunol. 18 (12): 1901–5. PMID 3220103. doi:10.1002/eji.1830181206.

Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, Thompson CB, Griesser H, Mak TW (novembro de 1995). "Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4". Science 270 (5238): 985–8. JSTOR 2888113. PMID 7481803. doi:10.2307/2888113.

Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH (novembro de 1995). "Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4" (PDF). Immunity 3 (5): 541–7. PMID 7584144. doi:10.1016/1074-7613(95)90125-6.

Pardoll, Drew M. (decembro de 2012). "Immunology beats cancer: a blueprint for successful translation". Nature Immunology 13 (12): 1129–1132. ISSN 1529-2916. PMC 4659410. PMID 23160205. doi:10.1038/ni.2392.

Krummel MF, Allison JP (1995). "CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation". J. Exp. Med. 182 (2): 459–65. PMC 2192127. PMID 7543139. doi:10.1084/jem.182.2.459.

Walunas TL, Bakker CY, Bluestone JA (1996). "CTLA-4 ligation blocks CD28-dependent T cell activation". J. Exp. Med. 183 (6): 2541–50. PMC 2192609. PMID 8676075. doi:10.1084/jem.183.6.2541.

Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA (agosto de 1994). "CTLA-4 can function as a negative regulator of T cell activation". Immunity 1 (5): 405–13. PMID 7882171. doi:10.1016/1074-7613(94)90071-x.

Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP (1992). "CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones". Nature 356 (6370): 607–9. PMID 1313950. doi:10.1038/356607a0.

Magistrelli G, Jeannin P, Herbault N, Benoit De Coignac A, Gauchat JF, Bonnefoy JY, Delneste Y (novembro de 1999). "A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells". Eur. J. Immunol. 29 (11): 3596–602. PMID 10556814. doi:10.1002/(SICI)1521-4141(199911)29:11<3596::AID-IMMU3596>3.0.CO;2-Y.

Lee KM, Chuang E, Griffin M, Khattri R, Hong DK, Zhang W, Straus D, Samelson LE, Thompson CB, Bluestone JA (1998). "Molecular basis of T cell inactivation by CTLA-4". Science 282 (5397): 2263–6. PMID 9856951. doi:10.1126/science.282.5397.2263.

Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, Baker J, Jeffery LE, Kaur S, Briggs Z, Hou TZ, Futter CE, Anderson G, Walker LS, Sansom DM (2011). "Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4". Science 332 (6029): 600–3. PMC 3198051. PMID 21474713. doi:10.1126/science.1202947.

Chen J, Ganguly A, Mucsi AD, Meng J, Yan J, Detampel P, Munro F, Zhang Z, Wu M, Hari A, Stenner MD, Zheng W, Kubes P, Xia T, Amrein MW, Qi H, Shi Y (febreiro de 2017). "Strong adhesion by regulatory T cells induces dendritic cell cytoskeletal polarization and contact-dependent lethargy". The Journal of Experimental Medicine 214 (2): 327–338. PMC 5294852. PMID 28082358. doi:10.1084/jem.20160620.

Knieke K, Lingel H, Chamaon K, Brunner-Weinzierl MC (2012). "Migration of Th1 lymphocytes is regulated by CD152 (CTLA-4)-mediated signaling via PI3 kinase-dependent Akt activation". PLoS ONE 7 (3): e31391. PMC 3295805. PMID 22412835. doi:10.1371/journal.pone.0031391.

Schneider H, Downey J, Smith A, Zinselmeyer BH, Rush C, Brewer JM, Wei B, Hogg N, Garside P, Rudd CE (setembro de 2006). "Reversal of the TCR stop signal by CTLA-4". Science 313 (5795): 1972–5. PMID 16931720. doi:10.1126/science.1131078.

Rudd CE, Taylor A, Schneider H (maio de 2009). "CD28 and CTLA-4 coreceptor expression and signal transduction". Immunol. Rev. 229 (1): 12–26. PMID 19426212. doi:10.1111/j.1600-065X.2009.00770.x.

Fife BT, Pauken KE, Eagar TN, Obu T, Wu J, Tang Q, Azuma M, Krummel MF, Bluestone JA (novembro de 2009). "Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal". Nat. Immunol. 10 (11): 1185–92. PMC 2778301. PMID 19783989. doi:10.1038/ni.1790.

Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD, Peggs KS, Ravetch JV, Allison JP, Quezada SA (2013). "Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma". J. Exp. Med. 210 (9): 1695–710. PMC 3754863. PMID 23897981. doi:10.1084/jem.20130579.

Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT, Schickel JN, Tran DQ, Stoddard J, Zhang Y, Frucht DM, Dumitriu B, Scheinberg P, Folio LR, Frein CA, Price S, Koh C, Heller T, Seroogy CM, Huttenlocher A, Rao VK, Su HC, Kleiner D, Notarangelo LD, Rampertaap Y, Olivier KN, McElwee J, Hughes J, Pittaluga S, Oliveira JB, Meffre E, Fleisher TA, Holland SM, Lenardo MJ, Tangye SG, Uzel G (2014). "Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4". Science 345 (6204): 1623–7. PMC 4371526. PMID 25213377. doi:10.1126/science.1255904.

Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A, Bulashevska A, Petersen BS, Schäffer AA, Grüning BA, Unger S, Frede N, Baumann U, Witte T, Schmidt RE, Dueckers G, Niehues T, Seneviratne S, Kanariou M, Speckmann C, Ehl S, Rensing-Ehl A, Warnatz K, Rakhmanov M, Thimme R, Hasselblatt P, Emmerich F, Cathomen T, Backofen R, Fisch P, Seidl M, May A, Schmitt-Graeff A, Ikemizu S, Salzer U, Franke A, Sakaguchi S, Walker LS, Sansom DM, Grimbacher B (2014). "Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations". Nat. Med. 20 (12): 1410–6. PMC 4668597. PMID 25329329. doi:10.1038/nm.3746.

Zeissig S, Petersen BS, Tomczak M, Melum E, Huc-Claustre E, Dougan SK, Laerdahl JK, Stade B, Forster M, Schreiber S, Weir D, Leichtner AM, Franke A, Blumberg RS (2014). "Early-onset Crohn's disease and autoimmunity associated with a variant in CTLA-4". Gut 64: 1–9. PMC 4512923. PMID 25367873. doi:10.1136/gutjnl-2014-308541.

Lee S, Moon JS, Lee CR, Kim HE, Baek SM, Hwang S, Kang GH, Seo JK, Shin CH, Kang HJ, Ko SJ, Park SG, Choi M (2016). "Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4". J Allergy Clin Immunol 137: 327–30. PMID 26478010. doi:10.1016/j.jaci.2015.08.036.

Westhovens, R., et al, Abatacept (CTLA4Ig) treatment increases the remission rate in rheumatoid arthritis patients refractory to methotrexate treatment Arquivado 28 de setembro de 2011 en Wayback Machine., Meeting Abstract, Arthritis Research & Therapy 6(Suppl 1):86, 24 de febreiro de 2004. doi 10.1186/ar1128. Consultado o 2015-11-14.

Pardoll DM (April 2012). "The blockade of immune checkpoints in cancer immunotherapy". Nat. Rev. Cancer 12 (4): 252–64. PMC 4856023. PMID 22437870. doi:10.1038/nrc3239.

Follows ER, McPheat JC, Minshull C, Moore NC, Pauptit RA, Rowsell S, Stacey CL, Stanway JJ, Taylor IW, Abbott WM (outubro de 2001). "Study of the interaction of the medium chain mu 2 subunit of the clathrin-associated adapter protein complex 2 with cytotoxic T-lymphocyte antigen 4 and CD28". Biochem. J. 359 (Pt 2): 427–34. PMC 1222163. PMID 11583591. doi:10.1042/0264-6021:3590427.

Peach RJ, Bajorath J, Naemura J, Leytze G, Greene J, Aruffo A, Linsley PS (setembro de 1995). "Both extracellular immunoglobin-like domains of CD80 contain residues critical for binding T cell surface receptors CTLA-4 and CD28". J. Biol. Chem. 270 (36): 21181–7. PMID 7545666. doi:10.1074/jbc.270.36.21181.

Stamper CC, Zhang Y, Tobin JF, Erbe DV, Ikemizu S, Davis SJ, Stahl ML, Seehra J, Somers WS, Mosyak L (marzo de 2001). "Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses". Nature 410 (6828): 608–11. PMID 11279502. doi:10.1038/35069118.

Baroja ML, Vijayakrishnan L, Bettelli E, Darlington PJ, Chau TA, Ling V, Collins M, Carreno BM, Madrenas J, Kuchroo VK (maio de 2002). "Inhibition of CTLA-4 function by the regulatory subunit of serine/threonine phosphatase 2A". J. Immunol. 168 (10): 5070–8. PMID 11994459. doi:10.4049/jimmunol.168.10.5070.

nih.gov

ncbi.nlm.nih.gov

Walunas TL, Bakker CY, Bluestone JA (1996). "CTLA-4 ligation blocks CD28-dependent T cell activation". J. Exp. Med. 183 (6): 2541–50. PMC 2192609. PMID 8676075. doi:10.1084/jem.183.6.2541.

Pardoll DM (April 2012). "The blockade of immune checkpoints in cancer immunotherapy". Nat. Rev. Cancer 12 (4): 252–64. PMC 4856023. PMID 22437870. doi:10.1038/nrc3239.

Chuang E, Alegre ML, Duckett CS, Noel PJ, Vander Heiden MG, Thompson CB (xullo de 1997). "Interaction of CTLA-4 with the clathrin-associated protein AP50 results in ligand-independent endocytosis that limits cell surface expression". J. Immunol. 159 (1): 144–51. PMID 9200449.

CTLA4 (Galician Wikipedia)

archive.org

arthritis-research.com

cell.com

doi.org

dx.doi.org

elsevier.com

linkinghub.elsevier.com

genenames.org

jstor.org

nih.gov

ncbi.nlm.nih.gov

web.archive.org

worldcat.org